The FDA has approved datopotamab deruxtecan-dlnk for certain patients with non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway) for the treatment of adult...
The FDA has approved tafasitamab-cxix for certain patients with follicular lymphoma. The U.S. Food and Drug Administration (FDA) has approved tafasitamab-cxix (Monjuvi) in combination with lenalidomide (Revlimid) and rituximab (Rituxan) for the treatment of...
The FDA has approved pembrolizumab for certain patients with previously untreated head and neck cancer. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) for the treatment of adult patients with resectable...
The FDA has approved mitomycin intravesical solution for certain patients with recurrent non-muscle invasive bladder cancer. The U.S. Food and Drug Administration (FDA) has approved mitomycin intravesical solution (Zusduri) for the treatment of adult...
The FDA has approved taletrectinib for certain patients with ROS1-mutated lung cancer. The U.S. Food and Drug Administration (FDA) has approved taletrectinib (Ibtrozi) for the treatment of adult patients with locally advanced or metastatic...
The FDA has approved darolutamide for metastatic castration-sensitive prostate cancer. The U.S. Food and Drug Administration (FDA) has approved darolutamide (Nubeqa) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). Darolutamide is...
The FDA has approved retifanlimab-dlwr, both alone and in combination with chemotherapy, for certain patients with anal squamous cell carcinoma. The U.S. Food and Drug Administration (FDA) has approved retifanlimab-dlwr (Zynyz) for patients with...
The FDA has approved telisotuzumab vedotin-tllv for certain patients with non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis) for the treatment of adult...
The FDA has approved belzutifan for certain patients with pheochromocytoma and paraganglioma. The U.S. Food and Drug Administration (FDA) has approved belzutifan (Welireg) for the treatment of patients 12 years and older with locally...
The FDA has approved avutometinib and defactinib for certain patients with KRAS-mutated low-grade serous ovarian cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to avutometinib and defactinib (Avmapki Fakzynja Co-pack)...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now